AI Summary
We reviewed 10 live results for nivestym (filgrastim aafi) and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Biosimilar and Hematology.
Comparison Table
Recommended
Nivestym (filgrastim-aafi)
Source: Pfizer
Description
Nivestym is a filgrastim biosimilar used to reduce the time to neutrophil recovery and the duration of fever following chemotherapy. It is used in patients with non-myeloid malignancies and those undergoing bone marrow transplantation.
Best for
managed care settings, chemotherapy-induced neutropenia, bone marrow transplant recipients and US oncology centers
View Details
Rating
Neupogen (filgrastim)
Source: Amgen
Description
Neupogen is the reference biologic (originator) medication containing recombinant filgrastim. It is used to stimulate bone marrow to produce white blood cells to prevent infections in patients with non-myeloid malignancies receiving myelosuppressive therapy.
Best for
reference biologic preference, established clinical protocols, severe chronic neutropenia and specialized oncology clinics
View Details
Rating
Neupogen (Filgrastim)
Source: Amgen
Description
A recombinant-methionyl human granulocyte colony-stimulating factor (r-metHuG-CSF) provided in pre-filled syringes. This haematopoietic agent is used to treat neutropenia and reduce the risk of infection in patients undergoing cancer treatments.
Best for
chemotherapy patients, neutropenia management, infection prevention and haematology support
View Details
Rating
| Compare | Nivestym (filgrastim-aafi) | Neupogen (filgrastim) | Neupogen (Filgrastim) |
|---|---|---|---|
| Source | Pfizer | Amgen | Amgen |
| Description | Nivestym is a filgrastim biosimilar used to reduce the time to neutrophil recovery and the duration of fever following chemotherapy. It is used in patients with non-myeloid malignancies and those undergoing bone marrow transplantation. | Neupogen is the reference biologic (originator) medication containing recombinant filgrastim. It is used to stimulate bone marrow to produce white blood cells to prevent infections in patients with non-myeloid malignancies receiving myelosuppressive therapy. | A recombinant-methionyl human granulocyte colony-stimulating factor (r-metHuG-CSF) provided in pre-filled syringes. This haematopoietic agent is used to treat neutropenia and reduce the risk of infection in patients undergoing cancer treatments. |
| Best for | managed care settings, chemotherapy-induced neutropenia, bone marrow transplant recipients and US oncology centers | reference biologic preference, established clinical protocols, severe chronic neutropenia and specialized oncology clinics | chemotherapy patients, neutropenia management, infection prevention and haematology support |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Nivestym (filgrastim-aafi) from Pfizer."
I picked this because A widely available, FDA-approved alternative biosimilar from a trusted global manufacturer, suitable for patients requiring cost-efficient G-CSF therapy in North America.
Share this search
Related Finds